1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2016

Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2016" provides an overview of Bile Duct Cancer (Cholangiocarcinoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Bile Duct Cancer (Cholangiocarcinoma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Bile Duct Cancer (Cholangiocarcinoma) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 442
Abbreviations 442
Definitions 442
Research Methodology 443
Secondary Research 443
About GlobalData 444
Contact Us 444
Disclaimer 444
Source 445

List of Tables
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Bile Duct Cancer (Cholangiocarcinoma) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 443

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

  • $ 5995
  • Industry report
  • December 2016
  • by GlobalData

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts Summary Companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Cancer Statistics in the Netherlands and the US

  • March 2017
    19 pages
  • Cancer  

    Hospital  

  • Netherlands  

    United States  

View report >

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Related Market Segments :

Cancer
Clinical Trial
Hepatitis
Therapy
Chemotherapy

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.